BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05941442 (Darigabat in Panic Disorder): BVCT ex-ante prediction vs. reported outcome

On 14 Feb 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 16 Apr 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05941442
Drug Name
Darigabat (CVL-865)
Drug MoA
subtype-selective GABAAR PAM
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Mental Disorders
Indication
Panic Disorder
Human Patients
80
Sponsor
AbbVie
Phase
Phase 2

Prediction of , index 1459

Prospective Prediction
Prediction Index
1459
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit non-superior and maybe inferior to benzodiazepine)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
792 days in advance
Readout Data Interpretation
Darigabat failed to meet the primary endpoint of panic attack-free days compared with placebo (P=0.75)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Phase
Phase 2
Status
Terminated
Enrollment
80
Lead sponsor
AbbVie
Conditions
Panic Disorder
Interventions
DRUG: Darigabat; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-07-31
Primary completion
2025-03-31
Completion
2025-03-31
Results first posted
2026-05-07
Primary outcomes
  • Percentage of Participants Free of Panic Attacks as Assessed by Participant Daily eDiary During the Last Two Weeks of the Maintenance Treatment Period (Week 13-14)

NCT05941442 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials